The estimated Net Worth of Gary Charles Robb is at least $13.6 million dollars as of 26 August 2024. Mr. Robb owns over 3,101 units of Corcept Therapeutics Inc stock worth over $824,405 and over the last 13 years he sold CORT stock worth over $10,172,961. In addition, he makes $2,610,360 as Chief Financial Officer et Secretary at Corcept Therapeutics Inc.
Gary has made over 24 trades of the Corcept Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 3,101 units of CORT stock worth $110,737 on 26 August 2024.
The largest trade he's ever made was exercising 451,852 units of Corcept Therapeutics Inc stock on 22 January 2021 worth over $1,220,000. On average, Gary trades about 25,025 units every 48 days since 2011. As of 26 August 2024 he still owns at least 23,190 units of Corcept Therapeutics Inc stock.
You can see the complete history of Mr. Robb stock trades at the bottom of the page.
Gary Charles Robb serves as Chief Financial Officer, Secretary of the Company. From 2005 to 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.
As the Chief Financial Officer et Secretary of Corcept Therapeutics Inc, the total compensation of Gary Robb at Corcept Therapeutics Inc is $2,610,360. There are 2 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
Gary Robb is 57, he's been the Chief Financial Officer et Secretary of Corcept Therapeutics Inc since 2014. There are 9 older and 8 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
Gary's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson et Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: